Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Khurana, Ashwani ^a   McKean, Hiedi ^a   Kim, Hyunseok ^b   Kim, Sung Hoon ^b   Mcguire, Jacie ^a   Roberts, Lewis R ^a   Goetz, Matthew P ^a   Shridhar, Viji ^a  

^a Mayo Clinic College of Medicine   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; GELATINASE B; HEPARAN ENDOSULFATASE 2; HEPARAN SULFATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; GENE SILENCING; HISTOPATHOLOGY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MORPHOLOGY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STAINING; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ZYMOGRAPHY; ANIMAL; BREAST TUMOR; DISEASE COURSE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; SULFOTRANSFERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862786672     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3140     Document Type: Article

References (39)

1. Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 2008, 112:2130-2142. 10.1002/cncr.23430, 18383519.
2. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004, 350:1430-1441. 10.1056/NEJMra031301, 15070793.
3. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16:441-452.
4. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Dimitrov N, Kavanah M. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000. 10.1016/S0140-6736(99)05036-9, 10376613.
5. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating mmp9 and transforming growth factor-{beta} signaling at the tumor-bone interface. Cancer Res 2010, 70:3494-3504. 10.1158/0008-5472.CAN-09-3251, 2862120, 20406980.
6. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001, 10:383-392.
7. Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, Sang QX. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004, 64:590-598. 10.1158/0008-5472.CAN-03-1932, 14744773.
8. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:201-212. 10.1007/s10911-010-9177-x, 2886087, 20440544.
9. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000, 60:2562-2566.
10. Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One 2011, 6:e18640. 10.1371/journal.pone.0018640, 3097176, 21611158.
11. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2010, 123:397-404. 10.1007/s10549-009-0654-0, 2976659, 19949854.
12. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annual Rev Biochem 1999, 68:729-777.
13. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Cir Res 2004, 94:316-323.
14. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002, 277:49175-49185. 10.1074/jbc.M205131200, 2779716, 12368295.
15. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson DA, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. FGFR signalling promotes the growth of triple negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011, 17:5275-5286. 10.1158/1078-0432.CCR-10-2727, 21712446.
16. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003, 278:23107-23117. 10.1074/jbc.M302203200, 12686563.
17. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, Shridhar V. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 2007, 282:14413-14420. 10.1074/jbc.M611395200, 17363371.
18. Locatelli A, Lange CA. Met receptors induce Sam68-dependent cell migration by activation of alternate extracellular signal-regulated kinase family members. J Biol Chem 2011, 286:21062-21072. 10.1074/jbc.M110.211409, 21489997.
19. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004, 23:1439-1447. 10.1038/sj.onc.1207258, 14973553.
20. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E, Miyamoto S. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008, 365:555-561. 10.1016/j.bbrc.2007.11.015, 18023415.
21. Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int J Cancer 2010, 127:2707-2717. 10.1002/ijc.25472, 20499311.
22. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 2007, 2:e392. 10.1371/journal.pone.0000392, 1849966, 17460759.
23. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005, 7:1001-1010. 10.1593/neo.05496, 1502017, 16331886.
24. Peterson SM, Iskenderian A, Cook L, Romashko A, Tobin K, Jones M, Norton A, Gomez-Yafal A, Heartlein MW, Concino MF, Liaw L, Martini PG. Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC Cancer 2010, 10:427. 10.1186/1471-2407-10-427, 2928797, 20707913.
25. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 2004, 6:R499-513. 10.1186/bcr899, 549167, 15318932.
26. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000, 92:1185-1186. 10.1093/jnci/92.14.1185, 10904098.
27. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006, 66:6025-6032. 10.1158/0008-5472.CAN-05-3582, 16778174.
28. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, Miller FR. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 2007, 120:2127-2134. 10.1002/ijc.22572, 17266026.
29. Khurana A, Nakayama K, Williams S, Davis RJ, Mustelin T, Ronai Z. Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem 2006, 281:35316-35326. 10.1074/jbc.M606568200, 2954258, 17003045.
30. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, Yang B, Linhardt RJ, Lingle W, Chien J, Baldi A, Shridhar V. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res 2011, 71:2152-2161. 10.1158/0008-5472.CAN-10-3059, 3059381, 21266348.
31. Khurana A, Tun HW, Marlow L, Copland JA, Dredge K, Shridhar V. Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol Carcinog 2011,
32. Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Front Biosci 2010, 15:226-236. 10.2741/3617, 2904307, 20036817.
33. Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther 2008, 7:1774-1782. 10.4161/cbt.7.11.6781, 18787417.
34. Ota I, Li XY, Hu Y, Weiss SJ. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci USA 2009, 106:20318-20323. 10.1073/pnas.0910962106, 2787166, 19915148.
35. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 2010, 30:1522-1528. 10.1111/j.1478-3231.2010.02336.x, 3042145, 21040406.
36. Otsuki S, Hanson SR, Miyaki S, Grogan SP, Kinoshita M, Asahara H, Wong CH, Lotz MK. Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways. Proc Natl Acad Sci USA 2010, 107:10202-10207. 10.1073/pnas.0913897107, 2890424, 20479257.
37. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology 2010, 52:1680-1689. 10.1002/hep.23848, 2967616, 20725905.
38. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010, 29:635-646. 10.1038/onc.2009.365, 2818095, 19855436.
39. Brown AM. WNT signaling in breast cancer: have we come full circle?. Breast Cancer Res 2001, 3:351-355. 10.1186/bcr321, 138699, 11737884.